Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
|Articles|October 25, 2021
Daily OTC Pearl: Azo (Phenazopyridine) for Urinary Tract Health
Author(s)Saro Arakelians, PharmD
Azo treats urinary pain, burning, urgency, and frequency associated with urinary tract infections.
Advertisement
OTC/Lifestyle Pearl of the Day: Azo (Phenazopyridine)
Indication: Relief from urinary pain, burning, urgency, and frequency associated with urinary tract infections.
Insight:
- Active ingredient in each tablet is phenazopyridine hydrochloride 97.5 mg.
- Dosing: Adults and children 12 years of age or older take 2 tablets 3 times daily, with or after meals, as needed for up to 2 days. Take with a full glass of water.
- Dosage forms: 95 mg, 97.2 mg, 100 mg, 200 mg.
- Directions to use: This medication should be taken by mouth, usually 3 times daily after meals or as directed by a physician.
- Adverse effects: Little or no urinating, swelling, confusion, fever, pale or yellowish skin, blue or purple appearance, headache, and dizziness.
- Do not use this medication while wearing soft contact lenses. Phenazopyridine can permanently discolor soft contact lenses.
Sources:
Advertisement
Related to this article
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Caitlin McClain, Peggy Lillis Foundation Board Member, Shares Her Experience With C difficile
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5